# Kinoxis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kinoxis-therapeutics-pty

- Industry: Pharmaceuticals
- Headquarters: Australia
- Website: www.kinoxistherapeutics.com
- Total disclosed funding: $17M
- Latest round: Series B (Apr 18, 2024)
- Investors on record: 18

## About

Based in Victoria, Australia, Kinoxis Therapeutics Pty Ltd was founded in 2017 by Hugh Alsop, Michael Bowen and Michael Kassiou as a University of Sydney spinout developing first-in-class small-molecule therapeutics for central nervous system disorders. As of September 2026, the company is led by its CEO, Hugh Alsop. On 22 September 2026, the company completed an AUD 6.75 million equity financing round led by new investor Main Sequence, with participation from existing investors Uniseed, UniSuper, The University of Sydney, Stoic VC, Avicella Capital and Individual Investor, to advance its ALOX15 inhibitor programs. Kinoxis Therapeutics is focused on developing small-molecule therapeutics that modulate brain pathways involved in social behaviour. The company's lead product, KNX100, is a novel compound under development for treating substance use disorders and managing symptoms such as agitation and aggression associated with neurodegenerative and neurodevelopmental disorders. KNX100 has completed Phase I clinical trials, demonstrating initial safety and tolerability in humans. In addition to KNX100, Kinoxis is advancing a second program centred on compounds that target the oxytocin receptor. This program explores selective partial agonism and positive allosteric modulation of the oxytocin receptor to enhance social functioning. The company earns revenue through its licensing agreement with Boehringer Ingelheim, which provides an upfront payment, research support payments, eligibility for research, preclinical, clinical, regulatory and commercial milestone payments, and royalties on future product sales. The company plans to use its September 2026 funding to advance its ALOX15 inhibitor programs, including completing KNX101 toxicology studies by the end of 2026, with initial CARES-X Phase 2 results for KNX100 expected in mid-2027, and plans to pursue partnerships for the development and commercialisation of its candidates.

## Funding rounds

- Series B, Apr 18, 2024, $9.4M — Uniseed, UniSuper, The University of Sydney - Australia, Brisbane Angels, Stoic Venture Capital, Perpetual Corporate Trust Limited, Uiit Pty Ltd, Tess Property Holdings Pty Limited, The Cylinder Company Pty Ltd, Moore Family Nominee Pty Limited, Avicella Capital, Alik Investments Pty Limited, Manos Capital Pty Ltd, Namarong Investments Pty Ltd
- Series A, Nov 30, 2020, $3.9M — The University of Sydney - Australia, Brisbane Angels, Perpetual Corporate Trust Limited, PAN Group, Uiit Pty Ltd, The Cylinder Company Pty Ltd, Moore Family Nominee Pty Limited, Alik Investments Pty Limited, Manos Capital Pty Ltd, Namarong Investments Pty Ltd
- Series A, Feb 13, 2018, $4.1M — The University of Sydney - Australia, Brisbane Angels, Atlas Advisors Australia, PAN Group, Uiit Pty Ltd, Bellwether Investments Pty Ltd, The Cylinder Company Pty Ltd, Moore Family Nominee Pty Limited, Alik Investments Pty Limited, Falkenheim Pty Ltd, Namarong Investments Pty Ltd

## Investors

- The University of Sydney - Australia — Series A, Series B
- Brisbane Angels (https://capitalatlas.ai/funds/brisbane-angels) — Series A, Series B
- Atlas Advisors Australia — Series A
- PAN Group — Series A
- Uiit Pty Ltd — Series A, Series B
- Bellwether Investments Pty Ltd — Series A
- The Cylinder Company Pty Ltd — Series A, Series B
- Moore Family Nominee Pty Limited — Series A, Series B
- Alik Investments Pty Limited — Series A, Series B
- Falkenheim Pty Ltd — Series A
- Namarong Investments Pty Ltd — Series A, Series B
- Perpetual Corporate Trust Limited — Series A, Series B
- Manos Capital Pty Ltd — Series A, Series B
- Uniseed (https://capitalatlas.ai/funds/uniseed) — Series B
- UniSuper — Series B
- Stoic Venture Capital (https://capitalatlas.ai/funds/stoic-venture-capital) — Series B
- Tess Property Holdings Pty Limited — Series B
- Avicella Capital — Series B